Keyphrases
A1 Receptor
100%
Blood Glucose
7%
Blood Pressure
7%
Cardiovascular Disease
7%
Cardiovascular Risk
100%
Cholesterol
15%
Cholesterol Levels
7%
Descriptive Data
7%
Diabetes Therapy
7%
Efficacy Endpoint
7%
Exenatide Once Weekly
7%
Fasting Plasma Glucose
7%
Five-factor
7%
Glucagon-like
100%
Glycated Hemoglobin A1c
7%
Glycemic Control
7%
Head-to-head Comparison
100%
Head-to-head Trials
7%
Heart Rate
7%
Heart Rate Data
7%
Hemoglobin A1c (HbA1c)
7%
Leading Causes of Death
7%
Liraglutide
7%
Lixisenatide
7%
Narrative Review
100%
Patient Treatment
7%
Pharmacokinetics
7%
Postprandial Glucose
7%
Randomized Clinical Trial
7%
Receptor Agonist
100%
Resting Heart Rate
7%
Safety Endpoints
7%
Short-acting
15%
Small Changes
7%
Systolic Blood Pressure
15%
Type 2 Diabetic Patients
7%
Varying Effects
7%
Nursing and Health Professions
Blood Pressure
7%
Body Weight
23%
Cardiovascular Disease
7%
Cardiovascular Risk
100%
Cholesterol Blood Level
23%
Cholesterol Level
7%
Factor A
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Glucose Level
15%
Glycosylated Hemoglobin
7%
Hemoglobin A1c
15%
Liraglutide
7%
Patient with Type 2 Diabetes
7%
Resting Heart Rate
7%
Systolic Blood Pressure
15%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Disease
7%
Cardiovascular Risk
100%
Exendin 4
7%
Factor A
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Glycosylated Hemoglobin
7%
Hemoglobin A1c
15%
Liraglutide
7%
Lixisenatide
7%
Non Insulin Dependent Diabetes Mellitus
7%
Pharmacokinetic
7%
Randomized Clinical Trial
7%